PLA1A expression as a diagnostic marker of BRAF-mutant metastasis in melanoma cancer

Abstract BRAF and NRAS are the most reported mutations associated to melanomagenesis. The lack of accurate diagnostic markers in response to therapeutic treatment in BRAF/NRAS-driven melanomagenesis is one of the main challenges in melanoma personalized therapy. In order to assess the diagnostic val...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gang Yang, Shuya Liu, Mazaher Maghsoudloo, Marzieh Dehghan Shasaltaneh, Parham Jabbarzadeh Kaboli, Cuiwei Zhang, Youcai Deng, Hajar Heidari, Maliheh Entezari, ShaoZhi Fu, QingLian Wen, Saber Imani
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/dcfc640f6f074ff08497882c637ba4bf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dcfc640f6f074ff08497882c637ba4bf
record_format	dspace
spelling	oai:doaj.org-article:dcfc640f6f074ff08497882c637ba4bf2021-12-02T17:05:46ZPLA1A expression as a diagnostic marker of BRAF-mutant metastasis in melanoma cancer10.1038/s41598-021-85595-72045-2322https://doaj.org/article/dcfc640f6f074ff08497882c637ba4bf2021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-85595-7https://doaj.org/toc/2045-2322Abstract BRAF and NRAS are the most reported mutations associated to melanomagenesis. The lack of accurate diagnostic markers in response to therapeutic treatment in BRAF/NRAS-driven melanomagenesis is one of the main challenges in melanoma personalized therapy. In order to assess the diagnostic value of phosphatidylserine-specific phospholipase A1-alpha (PLA1A), a potent lysophospholipid mediating the production of lysophosphatidylserine, PLA1A mRNA and serum levels were compared in subjects with malignant melanoma (n = 18), primary melanoma (n = 13), and healthy subjects (n = 10). Additionally, the correlation between histopathological subtypes of BRAF/NRAS-mutated melanoma and PLA1A was analyzed. PLA1A expression was significantly increased during melanogenesis and positively correlated to disease severity and histopathological markers of metastatic melanoma. PLA1A mRNA and serum levels were significantly higher in patients with BRAF-mutated melanoma compared to the patients with NRAS-mutated melanoma. Notably, PLA1A can be used as a diagnostic marker for an efficient discrimination between naïve melanoma samples and advanced melanoma samples (sensitivity 91%, specificity 57%, and AUC 0.99), as well as BRAF-mutated melanoma samples (sensitivity 62%, specificity 61%, and AUC 0.75). Our findings suggest that PLA1A can be considered as a potential diagnostic marker for advanced and BRAF-mutated melanoma.Gang YangShuya LiuMazaher MaghsoudlooMarzieh Dehghan ShasaltanehParham Jabbarzadeh KaboliCuiwei ZhangYoucai DengHajar HeidariMaliheh EntezariShaoZhi FuQingLian WenSaber ImaniNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Gang Yang Shuya Liu Mazaher Maghsoudloo Marzieh Dehghan Shasaltaneh Parham Jabbarzadeh Kaboli Cuiwei Zhang Youcai Deng Hajar Heidari Maliheh Entezari ShaoZhi Fu QingLian Wen Saber Imani PLA1A expression as a diagnostic marker of BRAF-mutant metastasis in melanoma cancer
description	Abstract BRAF and NRAS are the most reported mutations associated to melanomagenesis. The lack of accurate diagnostic markers in response to therapeutic treatment in BRAF/NRAS-driven melanomagenesis is one of the main challenges in melanoma personalized therapy. In order to assess the diagnostic value of phosphatidylserine-specific phospholipase A1-alpha (PLA1A), a potent lysophospholipid mediating the production of lysophosphatidylserine, PLA1A mRNA and serum levels were compared in subjects with malignant melanoma (n = 18), primary melanoma (n = 13), and healthy subjects (n = 10). Additionally, the correlation between histopathological subtypes of BRAF/NRAS-mutated melanoma and PLA1A was analyzed. PLA1A expression was significantly increased during melanogenesis and positively correlated to disease severity and histopathological markers of metastatic melanoma. PLA1A mRNA and serum levels were significantly higher in patients with BRAF-mutated melanoma compared to the patients with NRAS-mutated melanoma. Notably, PLA1A can be used as a diagnostic marker for an efficient discrimination between naïve melanoma samples and advanced melanoma samples (sensitivity 91%, specificity 57%, and AUC 0.99), as well as BRAF-mutated melanoma samples (sensitivity 62%, specificity 61%, and AUC 0.75). Our findings suggest that PLA1A can be considered as a potential diagnostic marker for advanced and BRAF-mutated melanoma.
format	article
author	Gang Yang Shuya Liu Mazaher Maghsoudloo Marzieh Dehghan Shasaltaneh Parham Jabbarzadeh Kaboli Cuiwei Zhang Youcai Deng Hajar Heidari Maliheh Entezari ShaoZhi Fu QingLian Wen Saber Imani
author_facet	Gang Yang Shuya Liu Mazaher Maghsoudloo Marzieh Dehghan Shasaltaneh Parham Jabbarzadeh Kaboli Cuiwei Zhang Youcai Deng Hajar Heidari Maliheh Entezari ShaoZhi Fu QingLian Wen Saber Imani
author_sort	Gang Yang
title	PLA1A expression as a diagnostic marker of BRAF-mutant metastasis in melanoma cancer
title_short	PLA1A expression as a diagnostic marker of BRAF-mutant metastasis in melanoma cancer
title_full	PLA1A expression as a diagnostic marker of BRAF-mutant metastasis in melanoma cancer
title_fullStr	PLA1A expression as a diagnostic marker of BRAF-mutant metastasis in melanoma cancer
title_full_unstemmed	PLA1A expression as a diagnostic marker of BRAF-mutant metastasis in melanoma cancer
title_sort	pla1a expression as a diagnostic marker of braf-mutant metastasis in melanoma cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/dcfc640f6f074ff08497882c637ba4bf
work_keys_str_mv	AT gangyang pla1aexpressionasadiagnosticmarkerofbrafmutantmetastasisinmelanomacancer AT shuyaliu pla1aexpressionasadiagnosticmarkerofbrafmutantmetastasisinmelanomacancer AT mazahermaghsoudloo pla1aexpressionasadiagnosticmarkerofbrafmutantmetastasisinmelanomacancer AT marziehdehghanshasaltaneh pla1aexpressionasadiagnosticmarkerofbrafmutantmetastasisinmelanomacancer AT parhamjabbarzadehkaboli pla1aexpressionasadiagnosticmarkerofbrafmutantmetastasisinmelanomacancer AT cuiweizhang pla1aexpressionasadiagnosticmarkerofbrafmutantmetastasisinmelanomacancer AT youcaideng pla1aexpressionasadiagnosticmarkerofbrafmutantmetastasisinmelanomacancer AT hajarheidari pla1aexpressionasadiagnosticmarkerofbrafmutantmetastasisinmelanomacancer AT malihehentezari pla1aexpressionasadiagnosticmarkerofbrafmutantmetastasisinmelanomacancer AT shaozhifu pla1aexpressionasadiagnosticmarkerofbrafmutantmetastasisinmelanomacancer AT qinglianwen pla1aexpressionasadiagnosticmarkerofbrafmutantmetastasisinmelanomacancer AT saberimani pla1aexpressionasadiagnosticmarkerofbrafmutantmetastasisinmelanomacancer
_version_	1718381820967387136

PLA1A expression as a diagnostic marker of BRAF-mutant metastasis in melanoma cancer

Ejemplares similares